http://debbiewilliamsassociates.co.uk/ditch_the_dairy.htm Chrones disease and ulcerated colitis. My mother suffered for over 35 plus years with this and had a colostomy bag as well after a spell in hospital in an unrelated illness she was in a coma for 9 days and when she came home through dietary changes she stopped suffering. Debbie changed her diet getting all dairy products out from cheese to pizza to cream cakes and milk . This stopped the pain as you will see in the video her mothers response when given some custard in the hospital how the pain came on very suddenly. Debbie herself steers clear of dairy as it seems to cause her to feel blocked up and other unpleasant side effects. Many people are lactose intolerant without realizing it and suffer low level discomfort from irritable bowel to cramping pains not knowing that dairy products may be causing this.Creating a meal plan for a couple of weeks and then gradually adding in one dairy based food at a time will let you know whether its a problem for you or not. Debbie's mother was able to have the occasional cream cake once a week and her body could handle it but after 6 years of following eating foods that Debbie prepared she started buying lots of junk food and eating out more often with cream cakes everyday the downfall was dramatic and despite Debbie trying to stop her this time as she had a new baby to contend with Olive went downhill fast and was dead within 6 months.There is a saying we are digging our graves with out teeth, the link above takes you to a hypnosis product ditch the dairy if you feel you are addicted to dairy foods and need help to get them out to test if this will help you. Also check out www.notmilkman.com where there are tons and tons of scientific references linking dairy to all sorts of diseases. Also if you would like to have a free hypnosis recording my 'Stop worrying and create a wonderful life will help you. You can get it free from here:http://www.debbiewilliamsassociates.co.uk/. Back to the top:http://www.youtube.com/my_videos_edit?ns=1&video_id=0NU5jAiSWuA
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced that it has acquired Ireland-based QUMAS, a leading global provider of Cloud-based and on-premises enterprise compliance software supporting regulatory and quality operations in life sciences and other highly regulated industries. The QUMAS acquisition further extends Accelrys’ informatics portfolio with the addition of mission-critical, end-to-end document and process management compliance solutions. Proven quality management solutions supported by robust content and business process management capabilities provided by QUMAS advance Accelrys’ ability to help customers better manage the scientific innovation lifecycle by reducing regulatory risks, lowering quality costs, improving compliance effectiveness and increasing operational efficiency in bringing new products to market.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62188-accelrys-acquires-compliance-and-quality-management-leader-qumas
Leading scientists have released the latest results of the large scale trials related to nuts consumption and health, particularly in myocardial infarction, stroke and cardiovascular diseases. Recent scientific studies show the benefits of regular intake of nuts, not only associated with cardiovascular health but also with renal function, diabetes, cognitive function, atherosclerosis, metabolic syndrome, inflammatory biomarkers, etc. It is important to highlight that scientific evidence demonstrates that eating nuts is not associated with a higher risk of weight gain, and even reinforce their importance as sources of key nutrients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62432-scientifically-proven-nuts-are-not-fattening
http://www.getthehormonecure.com Dr.
Sara Gottfried refuses to accept the traditional medical thinking that
feeling cranky, asexual, tapped out, and sleep-deprived is just part of
being female and aging, and that prescription medication will fix all
problems. In The Hormone Cure, she combines natural therapies with
rigorous scientific testing to help women feel fully alive, especially
in the years prior to menopause. Using an informative questionnaire to
identify common symptoms of hormonal imbalance such as insomnia, low
sex drive, lack of energy, moodiness, hot flashes, and more; detailing
causes; and offering solutions in non-judgmental and thoughtful
language, Dr. Gottfried provides a novel plan based on solid scientific
research. She believes you don't find a cure at the bottom of a pill
bottle.
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, has announced the launch of ScienceCloud, a new SaaS-based information management and collaboration workspace. ScienceCloud advances collaborative drug discovery with a new generation of integrated applications built on a scalable, cloud-based scientific platform. With no software to manage and no hardware to maintain, ScienceCloud improves operational excellence in globally networked research, significantly reducing IT cost and effort.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65595-sciencecloud-software-by-accelrys-advances-collaborative-drug-discovery
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced Accelrys Insight and Accelrys Insight for Excel, completing the roll-out of Accelrys’ next-generation cheminformatics suite and providing an interactive, collaborative environment for rapid and effective decision-making in drug discovery. Accelrys Insight and Accelrys Insight for Excel offer research scientists an entirely new way of accessing, visualizing and analyzing data that is locked in disparate locations across internal discovery teams and networked external partners, helping to lower long-standing barriers to bringing innovative therapeutics to market faster and more cost effectively.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62191-accelrys-insight-next-generation-decision-making-in-scientific-discovery
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced its next-generation mobile strategy for the laboratory―to provide a flexible and secure mobile computing environment that effectively connects scientists, equipment and materials in today’s laboratories where an increasing number and variety of mobile devices, from smart phones to tablet computers, are in use. With over a decade of experience in pioneering paperless, mobile computing and wireless compliance capabilities in regulated laboratories, Accelrys will empower organizations to deploy purpose-built mobile applications in the lab from research to manufacturing, satisfying specific workflow requirements in accordance with Good Manufacturing Practice.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65931-accelrys-capture-drives-next-generation-mobility-in-the-laboratory
In a world demanding more innovation faster from every organization, Great Work: How To Make a Difference People Love (McGraw-Hill Professional), is a landmark guide released today to help people everywhere become the catalysts for positive change their organizations need. The book, by employee engagement expert David Sturt with the O.C. Tanner Institute, mixes inspiration and aspiration with scientific research and profound business insights to help people ideate, innovate and deliver meaningful contributions at work.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63145-great-work-book
St. Jude Children’s Research Hospital, www.stjude.org, announced today the appointment of James R. Downing, M.D., as its new CEO, effective July 15, 2014. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital, which is leading the way the world understands, treats and defeats pediatric cancer and other catastrophic diseases. Downing’s primary focus immediately upon assuming the CEO office will be to oversee a new era of clinical, research and infrastructure expansion throughout the St. Jude global network. He succeeds Dr. William E. Evans, who is retiring from the position after 10 years and returning full time to his long-standing pharmacogenomics research program at St. Jude.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256651-st-jude-children-s-research-hospital-new-era-of-expansion-and-growth/
It’s the eve of the twenty-second century: a world where the dearly departed send postcards back from Heaven and evangelicals make scientific breakthroughs by speaking in tongues; where genetically engineered vampires solve problems intractable to baseline humans and soldiers come with zombie switches that shut off self-awareness during combat. And it’s all under surveillance by an alien presence that refuses to show itself.
Daniel Bruks is trapped on a ship bound for the center of the solar system. To his left is a grief-stricken soldier, obsessed by whispered messages from a dead son. To his right is a pilot who hasn’t yet found the man she’s sworn to kill on sight. A vampire and its entourage of zombie bodyguards lurk in the shadows behind. And dead ahead, a handful of rapture-stricken monks takes them all to a meeting with something they will only call “The Angels of the Asteroids.”
Their pilgrimage brings Dan Bruks, the fossil man, face-to-face with the biggest evolutionary breakpoint since the origin of thought itself. Find out more at http://us.macmillan.com/author/peterwatts. Scifi
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Subaru of America, Inc. today announced the completion of a Pet Travel Seat Pilot Study as part of its continued partnership with Center for Pet Safety (CPS), a registered 501(c)(3) non-profit research and consumer advocacy organization. Subaru and CPS have tested pet products most commonly used by pet parents when traveling. Phase one tested pet harnesses, phase two tested pet crates and carriers, and now, phase three has tested pet travel seats.
A pet travel seat is typically used in a vehicle to hold or elevate the pet, but does not offer full containment. The Pet Travel Seat Pilot Study found that while a pet travel seat may offer distraction prevention, it will likely not offer crash protection in the event of an accident, which could lead to injury of the pet and the human vehicle passengers. The quality of commonly available pet travel seats did not provide effective protection in a crash scenario.
Based on the scientific test evidence collected over the past four years, in part through its partnership with Subaru, CPS can now identify the safest travel options for most pets. For small dogs and cats, Center for Pet Safety recommends one of the 2015 Top Performing Carriers; for medium and large dogs either the 2015 Top Performing Crate - Gunner Kennels G1 Intermediate with 8' Tie Down Straps, or a Center for Pet Safety Certified Harness. To view top performing products and CPS Certified products, visit www.CenterforPetSafety.org.
To view the multimedia release go to:
http://www.multivu.com/players/English/7074158-subaru-cps-pet-travel-seat-study/
